| Rank |
Status |
Study |
| 1 |
Not yet recruiting
|
Pregabalin for the Treatment of Uremic Pruritus
| Condition: |
Uremic Pruritus |
| Interventions: |
Drug: pregabalin 75mg daily for 12 weeks; Drug: fexofenadine 60 mg daily for 12 weeks; Drug: placebo |
| Outcome Measures: |
The changes in Pruritus symptoms assessed by VAS; The changes in Pruritus score (PS), Skindex-10", "Brief Itching Inventory" and Itch Medical Outcomes Study |
|
| 2 |
Not yet recruiting
|
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
| Conditions: |
Uremic Pruritus; Pruritus |
| Interventions: |
Drug: nalbuphine HCl ER tablets 60 mg BID; Drug: nalbuphine HCl ER tablets 120mg BID; Drug: Placebo tablets BID |
| Outcome Measures: |
Change from Baseline to the Evaluation Period (weeks 7 and 8) in itch on the 0-10 Itch Numerical Rating Scale; Change from Baseline scores to the Evaluation Period (weeks 7 and 8) in the total Skindex-10 score |
|
| 3 |
Not yet recruiting
|
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study
| Condition: |
Pruritus |
| Interventions: |
Procedure: Biopsy; Procedure: Blood |
| Outcome Measures: |
the percentage change in pSTAT3 expression among patients reporting a relief in their Pruritus, irrespective of lesion clearing; IL-31 amount and intensity of cathepsin S expression; percentage of vasodilatory peptidergic nerves at the dermoepidermal junction as a percentage of total nerves |
|
| 4 |
Recruiting
|
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
| Condition: |
Treatment-resistant Pruritus Associated With Atopic Dermatitis |
| Interventions: |
Drug: VLY-686; Drug: Placebo |
| Outcome Measures: |
Efficacy of VLY-686 on reducing chronic Pruritus using Verbal Rating Scale (VRS) score and item 'Pruritus' of Patient Global Assessment (PGA) Likert scale; Efficacy of VLY-686 on reducing chronic Pruritus using Visual Analog Scale (VAS); Efficacy of VLY-686 on reducing atopic dermatitis skin lesions using SCORAD; Evaluate time course changes in VRS scores; Effect of VLY-686 on physiology of skin as measured by TransEpidermal Water Loss (TEWL); Effect of VLY-686 on the subjective measure of Patient Benefit Index (PBI).; Measurement of nerve fiber density and NK-1 receptor density in exploratory skin biopsies.; Number of adverse events in subjects taking placebo; Explore the contribution of genetic factors on safety outcomes (e.g. number of adverse events, changes in vital signs, changes in laboratory values).; Evaluate time course changes in VAS scores; Explore the contribution of genetic factors on efficacy outcomes (e.g. VRS, VAS, SCORAD); Number of adverse events in subjects taking VLY-686; Effect of VLY-686 on physiology of skin as measured by Skin Hydration.; Efficacy of VLY-686 on reducing atopic dermatitis skin lesions using Eczema Area and Severity Index (EASI); Effect of VLY-686 on the subjective measure of Dermatology Life Quality Index (DLQI).; Effect of VLY-686 on the Clinical Global Impression-Change (CGI-C). |
|
| 5 |
Unknown †
|
A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)
| Condition: |
Uremic Pruritus |
| Interventions: |
Drug: Nalfurafine HCl 2.5 µg; Drug: Nalfurafine HCl 5.0 µg; Other: Placebo |
| Outcome Measure: |
Primary efficacy endpoint is the change in worst itching intensity from baseline, compared to that in the last two weeks of the double blind, placebo controlled, randomized withdrawal period. |
|
| 6 |
Recruiting
|
Naloxone for the Treatment of Opioid-Induced Pruritus
| Condition: |
Pruritus |
| Interventions: |
Drug: Naloxone; Drug: Saline/Morphine |
| Outcome Measures: |
Pruritus incidence and intensity; Self-report pain scores; Morphine, ondansetron, diphenhydramine utilization |
|
| 7 |
Unknown †
|
Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus
| Condition: |
Uremic Pruritus |
| Interventions: |
Drug: Pregabalin; Drug: Placebo |
| Outcome Measures: |
Reduction of UP by more than 50% after Pregabalin administration; Reduction of chronic pain of various origin and improvement in insomnia after Pregabalin administration |
|
| 8 |
Recruiting
|
Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
| Conditions: |
Sezary Syndrome; Pruritus |
| Interventions: |
Drug: Aprepitant; Drug: Placebo |
| Outcome Measures: |
Severity of Pruritus; Quality of life |
|
| 9 |
Not yet recruiting
|
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
| Conditions: |
Uremic Pruritus; Pruritus |
| Interventions: |
Drug: nalbuphine HCl ER 60mg BID; Drug: nalbuphine HCl ER 90mg BID; Drug: nalbuphine HCl ER 120mg BID |
| Outcome Measures: |
A description of the overall incidence frequency and nature of Treatment Emergent Adverse Events (TEAEs); A description of the incidence frequency and nature of Treatment Emergent Adverse Events (TEAEs) during Treatment by achieved dose |
|
| 10 |
Recruiting
|
Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron
| Condition: |
Morphine Adverse Reaction |
| Interventions: |
Drug: Ondansetron; Drug: Palonosetron |
| Outcome Measure: |
Incidence of Pruritus |
|
| 11 |
Unknown †
|
Gabapentin - A Solution to Uremic Pruritus?
| Conditions: |
Pruritus; Uremia |
| Intervention: |
Drug: Gabapentin |
| Outcome Measures: |
Subjective measurement of reduction in Pruritus; Tolerability of Gabapentin in CAPD patients |
|
| 12 |
Not yet recruiting
|
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
| Condition: |
Alagille Syndrome |
| Interventions: |
Drug: LUM001; Drug: Placebo |
| Outcome Measure: |
Efficacy |
|
| 13 |
Recruiting
|
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus
| Condition: |
Cholestasis, Intrahepatic |
| Interventions: |
Drug: GSK2330672; Drug: Placebo; Drug: Ursodeoxycholic acid |
| Outcome Measures: |
Safety and tolerability assessment following repeat doses of GSK2330672; Tolerability assessment using Gastrointestinal Symptom Rating Scale (GSRS).; Fecal occult blood testing; Steady-state PK assessment of UDCA and its taurine and glycine conjugates taurodeoxycholic acid (TUDCA) and glycoursodeoxcholic acid (GUDCA); Plasma GSK2330672 PK assessment; Measurement of serum profiles of total bile acid concentrations and 7-alpha hydroxy-4-cholesten-3-one (C4); Subject reported outcomes - daily Pruritus 0 to 10 pt scale.; Subject reported outcomes - 5D-itch scale; Patient reported outcomes PBC-40 quality of life (QoL) scale. |
|
| 14 |
Unknown †
|
Treatment of Uremic Pruritus by Olive-omega 3 Ointment
| Condition: |
Uremic Pruritus |
| Intervention: |
Procedure: application of ointment (olive-omega 3 ointment) |
| Outcome Measure: |
|
|
| 15 |
Not yet recruiting
|
Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching
| Condition: |
Pruritus |
| Interventions: |
Drug: Cetirizine; Drug: Placebo or sugar pill |
| Outcome Measure: |
Itch score |
|
| 16 |
Recruiting
|
VPD-737 for Treatment of Chronic Pruritus
| Condition: |
Chronic Pruritus |
| Interventions: |
Drug: VPD-737; Drug: Placebo |
| Outcome Measures: |
Visual Analog Scale; Verbal Response Scale |
|
| 17 |
Recruiting
|
Hypnosis for Pain and Itch Following Burn Injuries
| Condition: |
Burns |
| Interventions: |
Behavioral: Hypnosis; Other: Standard of Care |
| Outcome Measures: |
Change in Numerical Rating Scale for Average Itch; Change in Numerical Rating Scale for Pain; Change in Medical Outcomes Study of Sleep; Change in Leeds Assessment of Neuropathic Symptoms and Signs-Self report; Change in 5-D Itch Scale; Change in Post-Traumatic Stress Disorder Checklist-Civilian version |
|
| 18 |
Recruiting
|
A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis
| Condition: |
Atopic Dermatitis |
| Interventions: |
Drug: CT327 ointment; Drug: placebo |
| Outcome Measures: |
• To determine whether CT327 is effective in reducing Pruritus in subjects with atopic dermatitis, using a Pruritus visual analogue scale (VAS); • To assess efficacy of CT327 on atopic dermatitis using the Investigator Global Assessment (IGA) |
|
| 19 |
Recruiting
|
Pruritus in Patients With Chronic Kidney Disease
| Conditions: |
Kidney Failure, Chronic; Pruritus |
| Intervention: |
Other: Questionnaire based on the McGill Pain Questionnaire |
| Outcome Measure: |
|
|
| 20 |
Unknown †
|
Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases
| Conditions: |
Eczema; Psoriasis |
| Interventions: |
Device: UVA / UVB phototherapy; Device: UVB phototherapy |
| Outcome Measure: |
5-D Pruritus score and VAS Score at 16 weeks |
|
